(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(0.52%) $78.52
(1.59%) $2.18
(0.08%) $2 310.50
(0.58%) $26.85
(-0.06%) $964.70
(0.03%) $0.929
(-0.18%) $10.85
(-0.04%) $0.797
(0.52%) $91.61
-92.64% $ 0.00850
Live Chart Being Loaded With Signals
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties...
Stats | |
---|---|
Dzisiejszy wolumen | 1.94M |
Średni wolumen | 876 957 |
Kapitalizacja rynkowa | 582 482 |
EPS | $0 ( 2023-11-08 ) |
Last Dividend | $0.110 ( 2023-04-11 ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.142 |
ATR14 | $0.00500 (58.82%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-02-15 | Hogan H Michael Iii | Buy | 0 | |
2022-12-30 | Weber David Allen | Sell | 91 636 | Common Stock |
2022-12-28 | Cayer Paul E | Sell | 40 054 | Common Stock |
2022-11-28 | Capps Vickie L | Sell | 42 242 | Common Stock |
2022-06-21 | Schroeder Theodore R | Buy | 27 500 | Stock Option (right to buy) |
INSIDER POWER |
---|
-37.03 |
Last 98 transactions |
Buy: 7 968 332 | Sell: 3 029 863 |
Wolumen Korelacja
Otonomy Inc Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Otonomy Inc Korelacja - Waluta/Towar
Otonomy Inc Finanse
Annual | 2021 |
Przychody: | $125 000 |
Zysk brutto: | $-245 000 (-196.00 %) |
EPS: | $-0.810 |
FY | 2021 |
Przychody: | $125 000 |
Zysk brutto: | $-245 000 (-196.00 %) |
EPS: | $-0.810 |
FY | 2020 |
Przychody: | $273 000 |
Zysk brutto: | $-915 000 (-335.16 %) |
EPS: | $-1.100 |
FY | 2019 |
Przychody: | $600 000 |
Zysk brutto: | $-312 000 (-52.00 %) |
EPS: | $-1.450 |
Financial Reports:
No articles found.
Otonomy Inc Dividends
(Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0.110 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.110 | 2023-04-11 |
Last Dividend | $0.110 | 2023-04-11 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.110 | -- |
Avg. Dividend % Per Year | 39.17% | -- |
Score | 4.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2023 | $0.110 | 117.50% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Royal | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -402.60 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.526 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0949 | 1.500 | -0.0565 | -0.0848 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 6.52 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 6.28 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 6.28 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.166 | -1.500 | 7.24 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -31.04 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.669 | 2.00 | -0.223 | -0.446 | [0 - 30] |
freeCashFlowPerShareTTM | -0.673 | 2.00 | -0.337 | -0.673 | [0 - 20] |
debtEquityRatioTTM | -0.0285 | -1.500 | -0.114 | 0.171 | [0 - 2.5] |
grossProfitMarginTTM | -1.960 | 1.000 | -10.00 | -10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -397.00 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -2.68 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.00131 | 0.800 | -3.32 | -2.66 | [0.5 - 2] |
Total Score | -3.12 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.0107 | 1.000 | -0.102 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0949 | 2.50 | -0.0363 | -0.0848 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.673 | 2.00 | -0.224 | -0.673 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.669 | 2.00 | -0.223 | -0.446 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -339.34 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -1.609 |
Otonomy Inc
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej